INOVIQ Ltd (ASX: IIQ) - Share Price
Current share price for IIQ : $0.230 0.01 (4.55%)+
INOVIQ Ltd (IIQ), an ASX-listed company, is engaged in exosome technology which is advancing diagnostics and therapeutics to transform cancer care. Its product portfolio includes commercial stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumours.
IIQ General Information +
| ASX Code | IIQ |
| Website | http://www.inoviq.com |
| Industry/Sector | Health Care Services |
| Market Cap ($M) | 32 |
| IIQ Share Price | $0.230 |
| Day High | $0.230 |
| Day Low | $0.205 |
| Last Close | $0.220 |
| IIQ Share Price Movement | $0.01 ( 4.55% ) |
Prices as at 16:40, 9 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
INOVIQ Ltd (IIQ) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from INOVIQ Ltd (IIQ) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
INOVIQ Ltd (IIQ) price-sensitive announcements
IIQ - EXO-OC algorithm and clinical study update
INOVIQ Ltd has been developing the EXO-OC™ test, an exosome-based blood test for ovarian c
INOVIQ Ltd (IIQ)
1 Jul 2026 | 9:10 AM
1 Jul 2026 | 9:10 AM
IIQ - Trading Halt
On 29 June 2026, INOVIQ Ltd (ASX: IIQ) announced a trading halt for its securities pending
INOVIQ Ltd (IIQ)
29 Jun 2026 | 8:44 AM
29 Jun 2026 | 8:44 AM
IIQ - Positive CAR-exosome data in ovarian cancer
INOVIQ Ltd has announced positive in vitro data regarding its CAR-exosome platform, which
INOVIQ Ltd (IIQ)
25 Jun 2026 | 8:46 AM
25 Jun 2026 | 8:46 AM
IIQ - Response to ASX Price Query
INOVIQ Ltd responded to an ASX Price Query regarding the recent increase in the price of i
INOVIQ Ltd (IIQ)
17 Jun 2026 | 4:47 PM
17 Jun 2026 | 4:47 PM
INOVIQ Ltd (IIQ) Recent ASX Announcements
IIQ Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$6.93 | -$6.20 | -12.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$6.55 | -$7.10 | -14.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$7.63 | -$8.30 | 40.00% | 0.00 | 0.00 | 0.00% | 0.0% |
IIQ Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Australian Clinical Labs Limited (ACL) | $425M | -0.0336 | 0.0000 | 0.0000 | 12.5897 | 0.0000 | 0.0000 | 5.48% | 0.00% | 0.00% |
| Healius Limited (HLS) | $280M | -4.7068 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Integral Diagnostics Limited (IDX) | $783M | -1.3095 | 0.5666 | 0.1667 | 27.4151 | 17.5000 | 15.0000 | 3.10% | 3.81% | 3.33% |
| INOVIQ Ltd (IIQ) | $33M | -0.1213 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Sonic Healthcare Limited (SHL) | $10,804M | 0.0625 | 0.1134 | 0.1484 | 20.4873 | 18.4007 | 16.0229 | 4.89% | 5.01% | 5.05% |
IIQ Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 1.47 | 0.00 |
| Market | 0.28 | 13.00 | 1.14 | 0.58 |
| Sector | 0.68 | 23.20 | 1.59 | 2.54 |
IIQ Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Philip (Phil) John Powell | Non-Executive Director | 17 Jun 2019 |
| Mr Geoffrey A. Cumming | Non-Executive Director | 28 Jul 2020 |
| Mr Robert (Max) Maxwell Johnston | Non-Executive Director | 17 Jun 2019 |
| Ms Mary Harney | Non-Executive Director | 1 Oct 2024 |
| Mr Peter Lynton Gunzburg | Non-Executive Director, Non-Executive Chairman | 20 Oct 2025 |
INOVIQ Ltd (IIQ) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 25 May 2026 | GUNZBURG, Peter | Buy | Indirect Shares | 4,812 | $0.325 | $1,563.900 |
| 22 May 2026 | GUNZBURG, Peter | Buy | Indirect Shares | 25,188 | $0.315 | $7,934.220 |
| 21 May 2026 | GUNZBURG, Peter | Buy | Indirect Shares | 13,000 | $0.320 | $4,160.000 |
See all changes in directors' interest & trades for INOVIQ Ltd (IIQ) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
IIQ Management
| Name | Position |
|---|---|
| Leearne Hinch | Chief Executive Officer |
| Mark Edwards | Chief Financial Officer,Company Secretary |
| DR GREGORY RICE | CHIEF SCIENTIFIC OFFICER |
IIQ Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in INOVIQ Ltd (IIQ). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 11,666,332 (10.46%) | Merchant Funds Management Pty Ltd |
IIQ Calendar of Events
| Date | Event |
|---|---|
| 17 February 2027 | Report (Interim) |
| 17 September 2026 | Report (Annual) |
| 21 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
